GlassScriptPhysician profile
David F Porter
NPI 1588673180
$3,031.82
in general payments reported to CMS, 2019-2025
22 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $594 · 2021: $496 · 2022: $123 · 2023: $276 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $502.06 | 2019-2021 | |
| Allergan, INC. | $310.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $249.41 | 2019-2020 | |
| Depuy Synthes Sales INC. | $233.08 | 2019-2021 | |
| Amarin Pharma, INC. | $190.84 | 2019-2022 | |
| Stryker Corporation | $167.98 | 2025 | Mako |
| Ossio INC | $150.00 | 2023 | |
| Zynex Medical, INC. | $146.57 | 2025 | Nexwave |
| Glaxosmithkline, LLC. | $136.85 | 2019 | |
| Zimvie INC. | $126.42 | 2023 | |
| Ironwood Pharmaceuticals, INC | $123.75 | 2019 | |
| Mannkind Corporation | $123.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.18 | 2021 | |
| Insmed, INC. | $117.00 | 2020 | |
| Arthrosurface Incorporated | $99.86 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $76.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $42.18 | 2019-2020 | |
| Ossdsign USA Incorporated | $32.91 | 2025 | Ossdsign Catalyst |
| Arbor Pharmaceuticals, INC. | $32.91 | 2022 | |
| Abbvie INC. | $26.02 | 2021 | |
| Althera Pharmaceuticals LLC | $12.99 | 2021 | |
| Zyla Life Sciences, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.